Skip to main content
. 2022 Jan;183:109152. doi: 10.1016/j.diabres.2021.109152

Fig. 2.

Fig. 2

Cost-effectiveness acceptability curves showing how the probability that exenatide is cost-effective compared with standard care varies with the ceiling ratio representing the value that society places on a QALY gained in a US setting (A) and in a UK setting (B).